ZYDUSLIFE Zydus Lifesciences Ltd Product Launches Announcement 2023 - Clinical Trial Initiation Zydus Lifesciences is initiating a Phase II clinical trial for the novel oral NLRP3 inflammasome inhibitor, ZYIL1, in patients with Amyotrophic Lateral Sclerosis (ALS)..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Zydus Lifesciences Ltd